Figure 6. Glaucine suppresses gpr126^st63 hypomorphic phenotype likely by direct interaction with Gpr126.

(A) Structures of aporphine compound series. Core scaffold highlighted in blue. (B) Toxicity screening of aporphines from 47-54 hpf. Survival was assessed at 54 hpf. All compounds were at 50 μM unless otherwise noted. Control, 1% DMSO. n≥10 in all cases. (C-G, I-K) PLLn mbp:gfp expression in 5 dpf gpr126^st63 (C-G) or gpr126^st49 (I-K) following 50 μM compound treatment at 47-54 hpf. Indicated region is the most anterior portion of the PLLn. Scale bar, 25 μm. Control, 1% DMSO. Note increased PLLn mbp:gfp expression in gpr126^st63 treated with glaucine (E) compared to control (C) but absence of mbp:gfp in glaucine-treated gpr126^st49 (J). (H) Quantification of PLLn mbp expression within ROI of gpr126^st63 larvae in C-G. Bars indicate means ± SD. ****p<0.0001, *p<0.05, one-way ANOVA with Dunnett’s multiple testing for each compound against control.